0001140361-26-019761
SEC filingBridgeBio Pharma entered into a new $500 million at-the-market equity offering agreement with Goldman Sachs and Leerink Partners, while terminating its prior 2023 agreement.
BridgeBio Pharma, Inc. established a new Equity Distribution Agreement on May 7, 2026, enabling flexible at-the-market sales of up to $500 million in common stock through Goldman Sachs & Co. LLC and Leerink Partners LLC. This replaces a prior agreement from May 4, 2023, terminated concurrently, providing the company with ongoing access to equity capital without commitment to specific sales volumes. The Sales Agents operate on a best efforts basis, adhering to normal practices and regulatory requirements, with compensation capped at 3% of gross proceeds plus standard indemnification. Sales can occur directly on Nasdaq or other markets using any legal ATM method under Rule 415. This structure offers strategic liquidity for funding operations or priorities, with full discretion to pause or end the program, enhancing capital management flexibility for investors.